Monocyte Chemiluminescence Traits in Gastric Cancer
https://doi.org/10.22416/1382-4376-2021-31-2-34-39
Abstract
Aim. A study of monocyte chemiluminescent activity at variant stages of gastric cancer.
Materials and methods. The study enrolled 90 gastric cancer patients and 70 healthy donors. Spontaneous and induced chemiluminescence in monocytes was assessed for 90 min with a “BLM 3607” 36-channel chemiluminescence analyser (Russia). Opsonized zymosan-induced chemiluminescence enhancement was measured as a ratio of the areas under the induced vs. spontaneous chemiluminescence curves, the activation index. Statistical significance was estimated with the Mann—Whitney criterion (p < 0.05).
Results. The maximal spontaneous monocyte chemiluminescence intensity significantly decreased in stage IV gastric cancer patients compared to the control cohort (p = 0.035). Time to maximum in spontaneous chemiluminescence increased in all gastric cancer patients vs. control (p = 0.001), and in stage IV gastric cancer vs. stage I patients (p = 0.043). The areas under a curve in spontaneous and induced monocyte chemiluminescence increased in all gastric cancer patients vs. control (p = 0.001), and in stage IV gastric cancer vs. stage I patients (p = 0.037). The activation index was higher in all gastric cancer cases compared to control (p = 0.001).
Conclusion. All patients with gastric adenocarcinoma, irrespective of the stage, revealed changes in the monocyte chemiluminescence activity, i.e. a longer time to maximum in spontaneous chemiluminescence and larger area under the curve of spontaneous and induced chemiluminescence, the activation index. Maximal monocyte spontaneous chemiluminescence intensity diminished in stage IV gastric cancer compared to the control cohort. Immune activity reflected in monocyte chemiluminescence correlates with the stage of gastric adenocarcinoma.
About the Authors
O. V. Smirnova
Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Olga V. Smirnova — Dr. Sci. (Med.), Head of the Laboratory of Clinical Pathophysiology
660022, Krasnoyarsk, Partizana Zheleznyaka str., 3Г
A. A. Sinyakov
Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Aleksandr A. Sinyakov — Cand. Sci. (Biol.), Researcher, Laboratory of Clinical Pathophysiology
660022, Krasnoyarsk, Partizana Zheleznyaka str., 3Г
V. V. Tsukanov
Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Vladislav V. Tsukanov— Dr. Sci. (Med.), Prof., Principal Researcher, Clinical Department of Adult and Infant Digestive Pathology
660022, Krasnoyarsk, Partizana Zheleznyaka str., 3Г
References
1. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. (eds.) Malignant neoplasms in Russia in 2019 (incidence and mortality). Moscow: Hertsen Moscow Oncology Research Center — Branch of NMRRC of the Ministry of Health of Russia, 2020 (In Russ.)
2. Oleynik E.K., Shibaev M.I., Oleynik V.M. Immunological status of gastrointestinal tumour patientsin Karelia. Immunology. 2004; 25(2):100–3 (In Russ.).
3. Solovyeva I.G., Egorov D.N., Cherenkova M.M., Vardosanidze K.V., Chernykh E.R., Abraov V.V. HLA-DR expression in monocytesand treatment outcomes in gastric cancer. Medical Immunology. 2004; 6(6):523–8 (In Russ.).
4. Arii K., Tanimura H., Iwahashi M., Tsunoda T., Tani M., Noguchi K., et al. Neutrophil functions and cytokine production in patients with gastric cancer. Hepatogastroenterology. 2000;47(31):291–7.
5. Bennett M.W., O’Сonnell J., O’Sullivan G.C., Roche D., Brady C., Kelly J., et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999;44(2):156–62. DOI: 10.1136/gut.44.2.156
6. Nagashima H., Mori M., Sadanaga N., Mashino K., Yoshikawa Y., Sugimachi K. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol. 2001;18(6):1157–62. DOI: 10.3892/ijo.18.6.1157
7. Yao X.X., Yin L., Sun Z.C. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. World J Gastroenterol. 2002;8(4):586–90. DOI: 10.3748/wjg.v8.i4.586
8. Antonov V.G., Kozlov V.K. Oncological pathogenesis: Immune and biochemical processes and mechanisms. Extracellular and cellular mechanisms of general immunosuppression and immune resistance. Cytokines and inflammation. 2004; 3(1): 8–19 (In Russ.).
9. Golovizin M.V. Interference of cancer cells in T-lymphocytematuration and selection as factor of tumour progression. Immunology. 2001;6: 4–10 (In Russ.).
10. Majima T., Ichikura T., Seki S., Takayama E., Hiraide H., Mochizuki H. Interleukin-10 and interferon-gamma levels within the peritoneal cavity of patients with gastric cancer. J Surg Oncol. 2001;78(2):124–30. DOI: 10.1002/jso.1131
11. Saito H., Tsujitani S., Oka S., Kondo A., Ikeguchi M., Maeta M., et al. The expression of transforming growth factor-beta1is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer (Philad). 1999;86(8):1455–62. DOI: 10.1002/(sici)1097-0142(19991015)86:83.0.co;2-L
12. Cherdyntseva N.V., Kolisho E.V., Kondakova I.V. Comparative ability of tumour associated and peritoneal murine macrophages to produce reactive oxygen species. Immunology. 1998;2: 39–42 (In Russ.).
Supplementary files
Review
For citations:
Smirnova O.V., Sinyakov A.A., Tsukanov V.V. Monocyte Chemiluminescence Traits in Gastric Cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(2):34-39. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-2-34-39
Views:
790
Email this article 
